Status: Recruiting
Treatment With Full-spectrum Cannabis Extract of Refractory Epilepsy Associated With Tuberous Sclerosis Complex (TSC)
1\. To assess treatment efficacy with YCJ-01 by changes in the number of epileptic seizures in patients with refractory epilepsy secondary to Tuberous Sclerosis Complex. 2. To assess the safety of the treatment with YCJ-01 in patients with refractory epilepsy secondary to Tuberous Sclerosis Complex.
Participants needed: 84
Trial details
Phase: Phase 3Age: 2-65Biological sex: AllType: InterventionalSponsor: Oils4CureUpdated: Feb 11, 2026Locations: 1
Eligibility criteria
Not listed